


PHARMACEUTICAL 2022

Jazz Pharmaceuticals.

Jazz Pharmaceuticals plc Rank 34 of 475








RealRate

PHARMACEUTICAL 2022





The relative strengths and weaknesses of Jazz Pharmaceuticals plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Jazz Pharmaceuticals plc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 224% points. The greatest weakness of Jazz Pharmaceuticals plc is the variable Other Expenses, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 164%, being 441% points above the market average of -276%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 2,611,334 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 8,979,937 |
| Liabilities, Current | 809,303 |
| Liabilities, Non-Current | 0 |
| Other Assets | 707,368 |
| Other Compr. Net Income | -266,008 |
| Other Expenses | 1,182,645 |
| Other Liabilities | 0 |
| Other Net Income | -283,830 |
| Property and Equipment | 0 |
| Research and Development | 505,748 |
| Revenues | 3,094,238 |
| Selling, General and Administrative Expense | 1,451,683 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 12,298,639 |
| Liabilities | 809,303 |
| Expenses | 3,140,076 |
| Stockholders Equity | 11,489,336 |
| Net Income | -329,668 |
| Comprehensive Net Income | -462,672 |
| Economic Capital Ratio | 164% |

